发布求助
文献互助 智能选刊 最新文献

Im Focus Onkologie最新文献

筛选
英文 中文
Neoadjuvante Chemoradiotherapie beim Ösophaguskarzinom
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4364-5
Kathrin von Kieseritzky
{"title":"Neoadjuvante Chemoradiotherapie beim Ösophaguskarzinom","authors":"Kathrin von Kieseritzky","doi":"10.1007/s15015-018-4364-5","DOIUrl":"https://doi.org/10.1007/s15015-018-4364-5","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"89 38 1","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78416776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seltene Hautkrebserkrankungen: Ursachen und neue Therapiestrategien 罕见皮肤癌:致病原因;全新的治疗方法
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-3609-7
R. Loewe
{"title":"Seltene Hautkrebserkrankungen: Ursachen und neue Therapiestrategien","authors":"R. Loewe","doi":"10.1007/s15015-018-3609-7","DOIUrl":"https://doi.org/10.1007/s15015-018-3609-7","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"1 1","pages":"65-69"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79927769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neoadjuvante platinbasierte Chemotherapie bei triplenegativem Brustkrebs sinnvoll?
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4351-x
J. Neumaier
{"title":"Neoadjuvante platinbasierte Chemotherapie bei triplenegativem Brustkrebs sinnvoll?","authors":"J. Neumaier","doi":"10.1007/s15015-018-4351-x","DOIUrl":"https://doi.org/10.1007/s15015-018-4351-x","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"55 1","pages":"36"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90571400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ALK-positives NSCLC: Zielgerichtete Therapie mit Brigatinib 领着训练营的蒂姆
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4398-8
Urike Hafner
{"title":"ALK-positives NSCLC: Zielgerichtete Therapie mit Brigatinib","authors":"Urike Hafner","doi":"10.1007/s15015-018-4398-8","DOIUrl":"https://doi.org/10.1007/s15015-018-4398-8","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"17 1","pages":"81 - 81"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84421947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nicht einfach nur ein weiteres Studienregister! 别慌
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4379-y
Springer Medizin
{"title":"Nicht einfach nur ein weiteres Studienregister!","authors":"Springer Medizin","doi":"10.1007/s15015-018-4379-y","DOIUrl":"https://doi.org/10.1007/s15015-018-4379-y","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"132 1","pages":"73"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79641384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rektumkarzinom: Nutzen von Oxaliplatin hängt vom Alter ab 抗青霉素的使用取决于年龄
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4365-4
J. Neumaier
{"title":"Rektumkarzinom: Nutzen von Oxaliplatin hängt vom Alter ab","authors":"J. Neumaier","doi":"10.1007/s15015-018-4365-4","DOIUrl":"https://doi.org/10.1007/s15015-018-4365-4","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"57 1","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83419055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Checkpointhemmerkombination zeigt intrakranielle Aktivität beim Melanom 我们通过变换装置进入Melanom
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4371-6
B. Kreutzkamp, S. Graß
{"title":"Checkpointhemmerkombination zeigt intrakranielle Aktivität beim Melanom","authors":"B. Kreutzkamp, S. Graß","doi":"10.1007/s15015-018-4371-6","DOIUrl":"https://doi.org/10.1007/s15015-018-4371-6","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"5 1","pages":"64"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73062555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erhaltungstherapie mit Olaparib beim BRCA-mutierten Eierstockrebs 定在brca变异的卵巢癌
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4399-7
Red.
{"title":"Erhaltungstherapie mit Olaparib beim BRCA-mutierten Eierstockrebs","authors":"Red.","doi":"10.1007/s15015-018-4399-7","DOIUrl":"https://doi.org/10.1007/s15015-018-4399-7","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"81 1","pages":"81 - 81"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81006214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab als Biosimilar zugelassen
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4397-9
Reimund Freye
{"title":"Trastuzumab als Biosimilar zugelassen","authors":"Reimund Freye","doi":"10.1007/s15015-018-4397-9","DOIUrl":"https://doi.org/10.1007/s15015-018-4397-9","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"49 1","pages":"81 - 81"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85889009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morbus Hodgkin: Ziel ist die Behandlung ohne Chemo- und Radiotherapie 目标是不进行化疗及放射治疗
Im Focus Onkologie Pub Date : 2018-12-01 DOI: 10.1007/s15015-018-4337-8
Springer Medizin
{"title":"Morbus Hodgkin: Ziel ist die Behandlung ohne Chemo- und Radiotherapie","authors":"Springer Medizin","doi":"10.1007/s15015-018-4337-8","DOIUrl":"https://doi.org/10.1007/s15015-018-4337-8","url":null,"abstract":"","PeriodicalId":13382,"journal":{"name":"Im Focus Onkologie","volume":"40 1","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88789960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信